Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women

被引:62
作者
Cook, JA
Cohen, MH
Grey, D
Kirstein, L
Burke, J
Anastos, K
Palacio, H
Richardson, J
Wilson, TE
Young, M
机构
[1] Univ Illinois, Dept Psychiat, Mental Hlth Serv Res Program, Chicago, IL 60603 USA
[2] Cook Cty Hosp, Core Ctr, Chicago, IL 60612 USA
[3] Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[4] Montefiore Med Ctr, Dept Epidemiol, Bronx, NY 10467 USA
[5] San Francisco Dept Publ Hlth, Dept Populat Hlth & Prevent, San Francisco, CA USA
[6] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA
[7] SUNY Hlth Sci Ctr, Dept Prevent Med & Community Hlth, Brooklyn, NY 11203 USA
[8] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA
关键词
D O I
10.2105/AJPH.92.1.82
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women's Interagency HIV Study. Methods, Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability, Results. Before the availability of HAART, the cohort's likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American, Conclusions, After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women's access to the most effective types of therapy.
引用
收藏
页码:82 / 87
页数:6
相关论文
共 29 条
[1]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[2]   Helping the urban poor stay with antiretroviral HIV drug therapy [J].
Bamberger, JD ;
Unick, J ;
Klein, P ;
Fraser, M ;
Chesney, M ;
Katz, MH .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (05) :699-701
[3]   The Women's Interagency HIV Study [J].
Barkan, SE ;
Melnick, SL ;
Preston-Martin, S ;
Weber, K ;
Kalish, LA ;
Miotti, P ;
Young, M ;
Greenblatt, R ;
Sacks, H ;
Feldman, J .
EPIDEMIOLOGY, 1998, 9 (02) :117-125
[4]   Protease inhibitor use among a community sample of people with HIV disease [J].
Bing, EG ;
Kilbourne, AM ;
Brooks, RA ;
Lazarus, EF ;
Senak, M .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 20 (05) :474-480
[5]  
CRYSTAL S, 1995, HEALTH SERV RES, V30, P593
[6]   The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States [J].
Cunningham, WE ;
Andersen, RM ;
Katz, MH ;
Stein, MD ;
Turner, BJ ;
Crystal, S ;
Zierler, S ;
Kuromiya, K ;
Morton, SC ;
St Clair, P ;
Bozzette, SA ;
Shapiro, MF .
MEDICAL CARE, 1999, 37 (12) :1270-1281
[7]   RACIAL AND ETHNIC-DIFFERENCES IN OUTCOME IN ZIDOVUDINE-TREATED PATIENTS WITH ADVANCED HIV DISEASE [J].
EASTERBROOK, PJ ;
KERULY, JC ;
CREAGHKIRK, T ;
RICHMAN, DD ;
CHAISSON, RE ;
MOORE, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (19) :2713-2718
[8]  
EDELSTEIN H, 1999, NAT C WOM HIV AIDS O
[9]   Delays in protease inhibitor use in clinical practice [J].
Fairfield, KM ;
Libman, H ;
Davis, RB ;
Eisenberg, DM ;
Phillips, RS .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1999, 14 (07) :395-401
[10]   ACCESS TO THERAPY IN THE MULTICENTER AIDS COHORT STUDY, 1989-1992 [J].
GRAHAM, NMH ;
JACOBSON, LP ;
KUO, V ;
CHMIEL, JS ;
MORGENSTERN, H ;
ZUCCONI, SL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (09) :1003-1012